What is changing in China CMC regulatory?
China is a commercial market with enormous potential for the biopharmaceutical industry but is transitioning from a national regulatory environment to one that is more harmonized with the global industry (still with some local specifics and complexities).
BioPhorum’s Post-Approval Strategy Team has been navigating this new Chinese regulatory environment through its many recent changes. To capture its learnings, the team has produced a poster titled What is changing in China CMC Regulatory?
It mentions a wide range of changes in areas such as pharmacopeia, e.g., more convergent monographs in CHP 2020 than any other version of the Chinese Pharmacopeia. It also talks about changes in submissions, such as excipients and primary packaging materials now need to be registered on the Chinese Drug Master File platform before use in products.
Importantly, the poster also summarizes what is not changing in areas such as analytical considerations, e.g., abnormal toxicity testing as the only recognized standard for the absence of toxicity is still done through animal testing on each imported batch.
The poster format is an efficient way to communicate a lot of information. It can be used by BioPhorum member organizations, displayed in a CMC regulatory office, used at CMC meetings, and shared with colleagues outside the regulatory function, e.g., the quality team.
|What is happening in China CMC and regulatory June 2022.pdf|
- Download 94
- File Size 7.51 MB
- File Count 1
- Create Date 10th June 2022
- Last Updated